Price T Rowe Associates Inc. MD lifted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 374.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,326,893 shares of the company's stock after purchasing an additional 1,047,245 shares during the quarter. Price T Rowe Associates Inc. MD owned 3.79% of Oruka Therapeutics worth $25,730,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at $144,000. Geode Capital Management LLC bought a new position in Oruka Therapeutics during the third quarter valued at about $343,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Oruka Therapeutics during the fourth quarter worth about $303,000. 56.44% of the stock is currently owned by institutional investors.
Oruka Therapeutics Price Performance
Oruka Therapeutics stock traded down $0.28 during trading hours on Tuesday, hitting $9.71. The company had a trading volume of 9,683 shares, compared to its average volume of 232,365. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The firm's fifty day moving average is $9.98 and its 200-day moving average is $15.93. The firm has a market capitalization of $363.36 million, a P/E ratio of -1.55 and a beta of 0.25.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.19. Analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.
Insider Activity at Oruka Therapeutics
In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the business's stock in a transaction dated Friday, February 14th. The stock was bought at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the acquisition, the insider now directly owns 4,148,428 shares in the company, valued at $47,458,016.32. This represents a 2.19 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have purchased 98,339 shares of company stock valued at $1,128,456. Corporate insiders own 22.67% of the company's stock.
Analysts Set New Price Targets
Several research firms have recently weighed in on ORKA. Wolfe Research began coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective for the company. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $39.86.
Get Our Latest Analysis on Oruka Therapeutics
About Oruka Therapeutics
(
Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
